SecSonar.com

Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Editas Medicine, Inc. (EDIT) is a Biotechnology company based in US with a market capitalization of $331.4M. Revenue grew 25.4% year-over-year and free cash flow was negative at -$165.8M. This page tracks EDIT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 246 employees · IPO Feb 3, 2016

Valuation

Valuation & price

$2.62 · as of May 17, 2026 · -36.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

12.15

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.15$2.94$1.72Jul 25Dec 25Jul 26Jul 7, 25$2.54Jul 9, 25$3.08Jul 11, 25$2.88Jul 15, 25$2.75Jul 17, 25$2.73Jul 21, 25$3.15Jul 23, 25$3.46Jul 25, 25$3.15Jul 29, 25$2.59Jul 31, 25$2.51Aug 4, 25$2.56Aug 6, 25$2.53Aug 11, 25$2.20Aug 13, 25$3.08Aug 15, 25$3.03Aug 19, 25$2.63Aug 21, 25$2.73Aug 25, 25$2.72Aug 27, 25$2.67Aug 29, 25$2.57Sep 3, 25$2.50Sep 5, 25$2.76Sep 9, 25$2.76Sep 11, 25$2.71Sep 16, 25$2.83Sep 18, 25$3.00Sep 22, 25$3.00Sep 24, 25$3.37Sep 26, 25$3.24Sep 30, 25$3.47Oct 2, 25$3.89Oct 6, 25$3.80Oct 8, 25$4.15Oct 10, 25$3.72Oct 14, 25$3.59Oct 16, 25$3.96Oct 21, 25$3.88Oct 23, 25$3.65Oct 27, 25$3.25Oct 29, 25$3.04Oct 31, 25$3.08Nov 4, 25$2.78Nov 6, 25$2.69Nov 10, 25$2.52Nov 12, 25$2.70Nov 14, 25$2.60Nov 18, 25$2.62Nov 20, 25$2.47Nov 25, 25$2.39Nov 28, 25$2.41Dec 2, 25$2.11Dec 4, 25$2.43Dec 8, 25$2.42Dec 10, 25$2.60Dec 12, 25$2.53Dec 16, 25$2.51Dec 18, 25$2.35Dec 22, 25$2.33Dec 24, 25$2.21Dec 29, 25$2.10Jan 2, 26$2.05Jan 6, 26$2.14Jan 8, 26$2.14Jan 12, 26$2.13Jan 14, 26$2.22Jan 16, 26$2.03Jan 21, 26$2.12Jan 23, 26$2.16Jan 27, 26$2.11Jan 29, 26$2.06Feb 2, 26$2.01Feb 4, 26$1.95Feb 9, 26$1.81Feb 11, 26$1.77Feb 13, 26$1.76Feb 18, 26$1.72Feb 20, 26$1.79Feb 24, 26$2.11Feb 26, 26$2.18Mar 2, 26$2.15Mar 4, 26$2.19Mar 6, 26$2.00Mar 10, 26$2.64Mar 12, 26$2.54Mar 17, 26$2.46Mar 19, 26$2.35Mar 23, 26$2.40Mar 25, 26$2.32Mar 27, 26$2.23Mar 31, 26$2.47Apr 2, 26$2.67Apr 7, 26$2.74Apr 9, 26$2.89Apr 13, 26$3.20Apr 15, 26$3.37Apr 17, 26$3.49Apr 22, 26$3.33Apr 24, 26$2.91Apr 28, 26$3.06Apr 30, 26$3.00May 4, 26$3.00May 6, 26$3.18May 8, 26$3.11May 12, 26$2.93May 14, 26$2.85May 18, 26$2.53May 20, 26$2.60May 22, 26$2.76May 28, 26$3.43Jun 1, 26$3.34Jun 3, 26$2.78Jun 5, 26$2.71Jun 9, 26$2.65Jun 11, 26$2.44Jun 15, 26$2.46Jun 17, 26$2.55Jun 22, 26$2.80Jun 24, 26$2.80Jun 26, 26$2.85Jul 2, 26$3.65
$1.6752-week range$4.15
Loading valuation history…

Fundamentals

Key fundamentals

$331.4M

Market cap

25.4%

Revenue growth (YoY)

100.0%

Gross margin

-$165.8M

Free cash flow (USD)

-$69.9M

Net debt

Net cash position

7.8%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$6.1MFY 2017$13.7MFY 2018$31.9MFY 2019$20.5MFY 2020$90.7MFY 2021$25.5MFY 2022$19.7MFY 2023$78.1MFY 2024$32.3MFY 2025$40.5M
$6.1M$40.5M

Free cash flow by year

2016 → 2025

FY 2016$-53.4MFY 2017$-11.5MFY 2018$-50.5MFY 2019$-46.8MFY 2020$-187.0MFY 2021$-171.8MFY 2022$-181.5MFY 2023$-136.9MFY 2024$-219.1MFY 2025$-165.8M
-$53.4M-$165.8M

Gross margin by year

2021 → 2025

FY 202180.2%FY 202267.8%FY 202392.2%FY 2024100.0%FY 2025100.0%
80.2%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 18, 2026Filing
  • Insider sellInsider Sell $2KBurkly Linda · EVP, CHIEF SCIENTIFIC OFFICER · $2KJun 5, 2026Filing
  • Insider sellInsider Sell $42KO'Neill Gilmore Neil · Director, CEO · $41.5KJun 5, 2026Filing
  • Insider sellInsider Sell $1KParison Amy · SVP, Chief Financial Officer · $1.3KJun 5, 2026Filing
  • 8-K eventPreclinical Data PresentationMay 26, 2026Filing
  • 8-K eventSales Agreement TerminationMay 26, 2026Filing
  • 8-K eventWarrant IssuanceMay 26, 2026Filing
  • 8-K eventPreclinical Data ReportMay 14, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing

Questions

Frequently asked questions

What is Editas Medicine, Inc.'s market cap?

Editas Medicine, Inc. (EDIT) has a market capitalization of $331.4M.

What is EDIT's P/E ratio?

A meaningful P/E ratio is not available for EDIT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is EDIT's price-to-book (P/B) ratio?

EDIT trades at 12.15 times book value per share.

Are insiders buying EDIT stock?

SEC Form 4 filings show no open-market insider buys at Editas Medicine, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

CMPX

Compass Therapeutics, Inc.

$334M

LCTX

Lineage Cell Therapeutics, Inc.

$334.1M

ABEO

Abeona Therapeutics Inc.

$336M

BCYC

Bicycle Therapeutics plc

$325.5M

EVMN

Evommune, Inc.

$324.9M

OABI

OmniAb, Inc.

$323.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.